Search clinical trials for: G2019S LRRK2 mutation

Total 3289 results

Escape Bio, Inc.
Engage Health Inc.; Sano

Terminated

Parkinson's Disease G2019S LRRK2 Genetic Testing Program

Parkinson's Disease

United States
Icahn School of Medicine at Mount Sinai
Massachusetts General Hospital; National Institute of Neurological Disorders...

Recruiting

LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease (BioPD)

Parkinson Disease | GBA Gene Mutation | LRRK2

United States
Escape Bio, Inc.
Momentum Pharma; Science 37

Terminated

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene

United States
Institut National de la Santé Et de la Recherche...

Unknown

Clinical, Molecular and by Neuroimaging of LRRK2 Mutations (LRRK2)

Parkinson's Disease

France
Xuanwu Hospital, Beijing
Michael J. Fox Foundation for Parkinson's Research

Completed

LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers

Parkinson Disease

China
Nantes University Hospital

Terminated

Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation (EnteroLarc)

Parkinson's Disease

France
University of Malaya
Michael J. Fox Foundation for Parkinson's Research; University of Dundee; Nextcea... and other collaborators

Unknown

LRRK2 G2385R Leucocyte and Urine Biomarker Study (LRRK2 G2385R)

Parkinson Disease

Malaysia
King's College London
GlaxoSmithKline

Completed

Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease

Parkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8

United Kingdom
Indiana University
Michael J. Fox Foundation for Parkinson's Research

Completed

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2) (PROGENI)

Parkinson Disease

United States, Canada
GlaxoSmithKline

Terminated

LRRK2 Mutation and Parkinson's Disease

Parkinson Disease

United Kingdom
Assistance Publique - Hôpitaux de Paris
France Parkinson Association

Unknown

Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET (INFLAPARK)

Healthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 Mutation

France
CENTOGENE GmbH Rostock

Recruiting

Rostock International Parkinson's Disease Study (ROPAD) (ROPAD)

Parkinson´s Disease

Spain, Israel, United Kingdom, United States, Germany, Albania, Belgium, Brazil, Canada, France, Greece, Italy, Portugal, Turkey, Norway
Michael J. Fox Foundation for Parkinson's Research
University Health Network, Toronto; University of Rochester; Indiana University

Completed

FoxBioNet: ECV (Extracellular Vesicle) 004

Parkinson Disease

United States
Denali Therapeutics Inc.

Completed

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Biogen

Completed

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

Parkinson's Disease

Belgium, United States, United Kingdom, Netherlands
Michael J. Fox Foundation for Parkinson's Research
University Health Network, Toronto; University of Rochester; Indiana University

Completed

Fox BioNet Project: ECV-003

Parkinson Disease

United States
Michael J. Fox Foundation for Parkinson's Research
University Health Network, Toronto; University of Rochester; Indiana University

Completed

Fox BioNet Project: LRRK2-002

Parkinson Disease

United States
University of Luebeck
CENTOGENE GmbH Rostock

Unknown

LIPAD - LRRK2 International Parkinson's Disease Study (LIPAD)

Parkinson's Disease and Parkinsonism

Germany
Tel-Aviv Sourasky Medical Center

Unknown

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

Parkinson Disease

Israel
Xiangya Hospital of Central South University

Recruiting

Chinese PD-LRRK2 Registry

Parkinson Disease

China
University of Rochester
Michael J. Fox Foundation for Parkinson's Research; Emerald Innovations

Active, not recruiting

Objective, Passive Assessment of LRRK2 Carriers (OPAL)

Parkinson Disease

United States
University of Alabama at Birmingham
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease

Parkinson's Disease

United States
Tel-Aviv Sourasky Medical Center
United States Department of Defense

Recruiting

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease

Parkinson Disease | GBA Gene Mutation | Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Israel
Servier

Completed

Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers (IRIS-CLE-LRRK2)

Parkinson Disease

France
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Faeth Therapeutics
GOG Foundation

Not yet recruiting

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer

Endometrial Cancer
Inozyme Pharma

Not yet recruiting

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Pseudoxanthoma Elasticum | Arterial Calcification | Gene Mutations | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency | Autosomal Recessive Hypophosphatemic Rickets Type 2
PYC Therapeutics

Not yet recruiting

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

Autosomal Dominant Optic Atrophy | Kjer Optic Atrophy | OPA1 Gene Mutation | Hereditary Optic Atrophies
Helse Møre og Romsdal HF

Not yet recruiting

ATTR Cardiac Amyloidosis in a Selected Population

Carpal Tunnel Syndrome | Cardiac Amyloidosis | ATTR Amyloidosis Wild Type | ATTR Gene Mutation
Shanghai Chest Hospital
Novartis; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; BeiGene

Not yet recruiting

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

KRAS Mutation-Related Tumors | Advanced Lung Cancer | Refractory Tumor

China
PYC Therapeutics

Not yet recruiting

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Eye Diseases | Retinal Degeneration | Retinal Dystrophies | Retinal Disease | Retinitis Pigmentosa 11

United States
Khondrion BV

Not yet recruiting

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases (KH176-301)

Mitochondrial Diseases | Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Maternally Inherited Diabetes and Deafness (MIDD) | Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, Korea, Republic of, Belgium, China, Japan, Taiwan, Denmark, Germany, Israel, Italy, United Kingdom, Bulgaria, Portugal, Switzerland, Greece, Turkey, Sweden, France, Singapore, Mexico, Spain, Netherlands, Poland, Brazil, A... and more
Juan Pablo Romero. MD, PhD
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Not yet recruiting

Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease (PROGENS-PD)

Parkinson Disease

Spain
Anhui Medical University

Not yet recruiting

Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases

Mitochondrial Diseases
Blokhin's Russian Cancer Research Center

Recruiting

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer (GENCONCOR-1)

Colorectal Cancer Metastatic | Brain Metastases, Adult | HER2 Gene Mutation | MSI | BRAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation

Russian Federation
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Gastrointestinal Cancer | CRC | Metastatic Pancreatic Ductal Adenocarcinoma | PDAC

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

First Human Trial of Targeting MDM2/MDMX PET Imaging

Nuclear Medicine | MDM2/MDMX Gene Mutation | Positron Emission Tomography Imaing
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma | Thyroid Gland Oncocytic Carcinoma

United States
Massachusetts General Hospital

Not yet recruiting

Ziftomenib Maintenance Post Allo-HCT

Acute Myeloid Leukemia | Acute Myeloid Leukemia in Remission | NPM1 Mutation | KMT2A Rearrangement

United States
Novartis Pharmaceuticals

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (SPARKLE)

Sickle Cell Disease
Splice Bio

Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene (POLARIS)

Stargardt Disease | Stargardt's Disease | STGD1 | Stargardt
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Assiut University

Not yet recruiting

Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients

EKLF Mutations in Beta Thalassemia Patients
Centre Hospitalier Universitaire Dijon

Recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation (PRO-NEM1)

Neuroendocrine Tumors | MEN1 Mutation

France
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Novartis Pharmaceuticals

Not yet recruiting

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (ASC4INDIA)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Quanta Therapeutics

Recruiting

QTX3046 in Patients With KRAS G12D Mutations

Advanced Solid Tumor

United States

Search clinical trials for: G2019S LRRK2 mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations